This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Witzig, T. E. Search for Related Content PubMed PubMed Citation Articles by Witzig, T. E. Social Bookmarking                            What's this?

Current Treatment Approaches for Mantle-Cell Lymphoma

Thomas E. Witzig

From the Mayo Clinic College of Medicine and Mayo Foundation Rochester, MN

Address reprint requests to Thomas E. Witzig, MD, Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905; e-mail: Witzig{at}mayo.edu.

Mantle-cell lymphoma (MCL) is now recognized as a distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma. Patients with MCL are typically older adults with a male predominance and usually present with stage IV disease. The cells are characterized as CD20⁺ CD5⁺ CD23^– with a t(11;14)(q13;q32) and cyclin D1 overexpression on immunohistochemistry. Response to chemotherapy usually results in a tumor response but unmaintained remissions are short and the median survival is 3 to 4 years. The treatment approach to newly diagnosed patients with MCL depends on the patient's eligibility for stem cell transplantation (SCT). Those who are eligible are usually treated with either rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by SCT or rituximab-HyperCVAD (cyclophosphamide, vincristine, doxorubicin, decadron, cytarabine, and methotrexate) followed by observation. The purine nucleoside analogues also have activity as single agents and with rituximab. Unfortunately none of these approaches can definitively cure patients with MCL, and new agents are needed. Recent studies in patients with relapsed MCL have shown substantial antitumor activity of single-agent bortezomib, single-agent temsirolimus, and the combination of thalidomide and rituximab. Studies integrating these novel agents earlier in the disease course or in combination with each other will hopefully produce more durable responses with less toxicity.

Supported in part by Grants No. CA97274 and CA25224 from the National Institutes of Health and the National Cancer Institute.

Author's disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Delmonte, M. Ghielmini, and C. Sessa Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas Oncologist, May 1, 2009; 14(5): 511 - 525. [Abstract] [Full Text] [PDF]

				A. Goy, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study Ann. Onc., March 1, 2009; 20(3): 520 - 525. [Abstract] [Full Text] [PDF]

				G. Roue, M. Lopez-Guerra, P. Milpied, P. Perez-Galan, N. Villamor, E. Montserrat, E. Campo, and D. Colomer Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling Clin. Cancer Res., November 1, 2008; 14(21): 6907 - 6915. [Abstract] [Full Text] [PDF]

				E. Hartmann, V. Fernandez, V. Moreno, J. Valls, L. Hernandez, F. Bosch, P. Abrisqueta, W. Klapper, M. Dreyling, E. Hoster, et al. Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue J. Clin. Oncol., October 20, 2008; 26(30): 4966 - 4972. [Abstract] [Full Text] [PDF]

				P. H. Wiernik, I. S. Lossos, J. M. Tuscano, G. Justice, J. M. Vose, C. E. Cole, W. Lam, K. McBride, K. Wride, D. Pietronigro, et al. Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., October 20, 2008; 26(30): 4952 - 4957. [Abstract] [Full Text] [PDF]

				R. W. Chen, L. T. Bemis, C. M. Amato, H. Myint, H. Tran, D. K. Birks, S. G. Eckhardt, and W. A. Robinson Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma Blood, August 1, 2008; 112(3): 822 - 829. [Abstract] [Full Text] [PDF]

				S. Sander, L. Bullinger, E. Leupolt, A. Benner, D. Kienle, T. Katzenberger, J. Kalla, G. Ott, H. K. Muller-Hermelink, T. F.E. Barth, et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations Haematologica, May 1, 2008; 93(5): 680 - 687. [Abstract] [Full Text] [PDF]

				S. Michopoulos, K. Petraki, C. Matsouka, E. Kastritis, H. Chrysanthopoulou, and M. A. Dimopoulos Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract J. Clin. Oncol., March 20, 2008; 26(9): 1555 - 1557. [Full Text] [PDF]

				F. Morschhauser, J. F. Seymour, H. C. Kluin-Nelemans, A. Grigg, M. Wolf, M. Pfreundschuh, H. Tilly, J. Raemaekers, M. B. van 't Veer, N. Milpied, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma Ann. Onc., February 1, 2008; 19(2): 247 - 253. [Abstract] [Full Text] [PDF]

				A. Ferrer, F. Bosch, N. Villamor, M. Rozman, F. Graus, G. Gutierrez, S. Mercadal, E. Campo, C. Rozman, A. Lopez-Guillermo, et al. Central nervous system involvement in mantle cell lymphoma Ann. Onc., January 1, 2008; 19(1): 135 - 141. [Abstract] [Full Text] [PDF]

				N. Kawamata, J. Chen, and H. P. Koeffler Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells Blood, October 1, 2007; 110(7): 2667 - 2673. [Abstract] [Full Text] [PDF]

				M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera, and Q. Yi Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways Blood, June 15, 2007; 109(12): 5455 - 5462. [Abstract] [Full Text] [PDF]

				F Morschhauser, S Depil, E Jourdan, M Wetterwald, R Bouabdallah, G Marit, P Solal-Celigny, C Sebban, B Coiffier, N Chouaki, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma Ann. Onc., February 1, 2007; 18(2): 370 - 375. [Abstract] [Full Text] [PDF]

				R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma J. Clin. Oncol., October 20, 2006; 24(30): 4867 - 4874. [Abstract] [Full Text] [PDF]